Immunophenotypic Characterisation Along with Aberrant Expression of CD markers in Morphologically Diagnosed Cases of Acute Myeloid Leukemia

Authors

  • Salina Haque Assistant Professor, Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
  • Zulfia Zinat Chowdhury Medical Officer, Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
  • Tamanna Bahar Assistant Registrar, Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
  • Samira Taufique Reshma Assistant Professor, Department of Haematology, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh
  • AKM Mynul Islam Associate Professor, Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
  • Mohammad Ali Associate Professor and Head of Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
  • Jannatul Ferdouse Associate Professor, Department of Transfusion Medicine, Mugda Medical College, Dhaka, Bangladesh
  • Md Mahbubur Rahman Vice Chancellor, Sheikh Hasina Medical University, Khulna. Ex- Professor and Head of Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/jom.v23i2.60626

Keywords:

Acute myeloid leukemia, immunophenotyping, aberrant expression, CD markers

Abstract

Immunophenotyping of leukemia cells is useful for detecting leukemia cell line, determining maturation stage and identifying aberrant antigens which act for individual treatment monitoring and detection of residual disease. A total of 104 newly diagnosed cases of acute myeloid leukemia were identified at hematology department in National Institute of Cancer Research and Hospital from January 2020 to December 2021.We detect Immunophenotypic pattern in newly diagnosed cases of acute myeloid leukemia. We also determine the frequency and pattern of aberrant expression of CD markers in acute myeloid leukemia patients. Mean age of patients was 35 years (SD±16 years) with male to female ratio was 1.53:1. Most frequent morphologic subtype was AMLM2 constituting 33.6% of all AML cases. Lineage specific markers HLADR, CD13, CD33, MPO, CD117 and CD34 were expressed in 80%, 89%, 95%, 77%, 74% and 62% cases of all AML cases respectively. Among 104 AML patient, aberrant CD expression was observed in 36% cases. The most frequently observed aberrant markers were CD7 and CD19 lymphoid markers, that were expressed in 15.38% and 14.42% cases respectively. Less frequent aberrant cCD3, CD10, CD5 and cCD79a antigens were expressed in 2.88%, 1.92%, 0.96% and 0.96% cases respectively. Immunophenotyping is essential in diagnosis and sub-classification of AML and expression of aberrant CD antigens is common in acute myeloid leukemia. These findings suggest the necessity for a more extensive study to evaluate the prognostic significance of aberrant CD marker expression in AML and to improve the accuracy of diagnosis and classification of AML.

J MEDICINE 2022; 23: 106-111

Downloads

Download data is not yet available.
Abstract
77
PDF
67

Downloads

Published

2022-07-24

How to Cite

Haque, S. ., Chowdhury, Z. Z. ., Bahar, T. ., Reshma, S. T. ., Islam, A. M. ., Ali, M. ., Ferdouse, J. ., & Rahman, M. M. . (2022). Immunophenotypic Characterisation Along with Aberrant Expression of CD markers in Morphologically Diagnosed Cases of Acute Myeloid Leukemia. Journal of Medicine, 23(2), 106–111. https://doi.org/10.3329/jom.v23i2.60626

Issue

Vol. 23 No. 2 (2022)

Section

Original Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).